Posted by Michael Wonder on 06 Nov 2020
Xtandi (enzalutamide soft capsules) approved by China NMPA for the treatment of non-metastatic castration-resistant prostate cancer
6 November 2020 - Enzalutamide is now NMPA approved for both non-metastatic and metastatic castration-resistant prostate cancer.
Astellas Pharma today announced that the China National Medical Products Administration has approved Xtandi (enzalutamide soft capsules) for the treatment of adult men with non-metastatic castration-resistant prostate cancer with high risk of metastasis.
